Regeneron Pharmaceuticals (NASDAQ:REGN) EVP Marion Mccourt Sells 1,215 Shares of Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) EVP Marion Mccourt sold 1,215 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00. Following the completion of the sale, the executive vice president directly owned 13,134 shares in the company, valued at approximately $11,163,900. This represents a 8.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marion Mccourt also recently made the following trade(s):

• On Thursday, September 3rd, Marion Mccourt sold 1,131 shares of Regeneron Pharmaceuticals stock. The stock was sold at an average price of $857.39, for a total value of $969,708.09.

Regeneron Pharmaceuticals Price Performance

REGN opened at $843.47 on Friday. The firm has a market cap of $86.84 billion, a PE ratio of 20.85, a P/E/G ratio of 1.67 and a beta of 0.20. The stock has a 50-day moving average price of $734.39 and a 200-day moving average price of $719.34. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $859.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same period in the previous year, the business earned $12.81 EPS. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently bought and sold shares of REGN. SHP Wealth Management bought a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $26,000. Western Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth $26,000. Titan Wealth CI Ltd bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth $29,000. Mowery & Schoenfeld Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $29,000. Finally, Trust Co. of Vermont bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at about $29,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on REGN. Canaccord Genuity Group cut their target price on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Truist Financial increased their target price on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. BMO Capital Markets cut their price target on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Finally, Sanford C. Bernstein raised shares of Regeneron Pharmaceuticals to a “hold” rating in a research note on Wednesday, July 29th. Fourteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $800.36.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported that a Phase 1/2 study combining cemiplimab with SNS-101 has reached completion. The update provides a development milestone, although no efficacy or regulatory data were disclosed, limiting its immediate impact. Regeneron’s Cemiplimab Combo Trial With SNS-101 Reaches Completion
• Neutral Sentiment: Industry research projects substantial growth in the global complement-inhibitor market through 2035 and lists Regeneron among the leading companies. The report supports the company’s long-term opportunity but does not provide a new company-specific catalyst. 2026 Complement Inhibitors Market Analysis Report
• Negative Sentiment: Multiple law firms announced or promoted securities class actions involving investors who purchased REGN shares between August 1, 2025, and May 15, 2026. The lawsuits allege that Regeneron and certain executives misrepresented risks surrounding the Phase 3 Fianlimab-Libtayo melanoma trial, including a protocol change and eventual failure to meet its primary endpoint. Investors have until September 14, 2026, to seek lead-plaintiff status. The legal claims may increase reputational, litigation, and potential financial risks, although the allegations have not been proven. Hagens Berman Regeneron Securities Fraud Class Action Alert Robbins Geller Regeneron Investor Alert
• Negative Sentiment: Director Kathryn Guarini and EVP Marion McCourt reported sales totaling roughly $2.34 million. All transactions were executed under pre-arranged Rule 10b5-1 plans, reducing their significance as discretionary bearish signals, but the sales can still weigh on sentiment near the stock’s recent highs. SEC insider transaction filing

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.